Shipping is one thing; selling is another. All the Taxus product on the shelf is on consignment (i.e., no one buys it until it is implanted). Based upon what I am hearing BSX is getting A LOT of pushback. Pricing is just a bit ABOVE Cordis in most accounts; recent stories showing deliverability is a big issue for Taxus (worse not better delivery than Cypher); long term data are absent, BSX reps extremely arrogant that they deserve 70% market share with a product with 4 times more late loss, less deliverability, no long term data and no meaninful subset data, and reports of major adverse events at overlap sites. GDT is taking a huge bite out of the antagonsim towards Cordis, in those accounts where Cordis did not have a good relationship. That factor alone will cut BSX sales to half of original estimates. GDT is kicking BSX butt! The news on sales (even in this complete honeymoon period "Hey let's try it, it's NEW !!!") will be very disappointing to the street. Low $30s within 4-5 weeks.